Kuidas keskusega ühendust võtta
HCP keskus
Kontrollitava kõrge kvaliteedi pakkumine
Osaleva ja personaalse tervishoiu pakkumine
Kasutame oma ressursse tõhusalt
Osalemine jätkusuutlikes professionaalsetes võrgustikes igas valdkonnas
Radboudumci oftalmoloogiaosakond on erinevate silmahaiguste tippkeskus ning juhtiv ekspert võrkkesta haiguste ravis ja ravis. Lisaks igapäevasele kliinilisele hooldusele uurime võrkkesta haigusi. Meie uurimistöö peamisteks eesmärkideks on nende haiguste molekulaarse aluse parem mõistmine ning uute diagnostikaseadmete ja ravimeetodite väljatöötamine.
Radboudumci inimgeneetika osakond viib läbi murrangulisi uuringuid geenide ja haiguste vaheliste seoste kohta. Inimgeneetika osakonnas tehtavat patsiendihooldust (kliinilise geneetika jaoskond) ja geneetilist diagnostikat (jaoskonnagenoomi diagnostika) korraldab ametlik ja tunnustatud kliinilise geneetika keskus.
Pilt : .Koen
Saada sõnum
Radboud university medical center, Nijmegen, Netherlands
meeskond
Pr Carel HOYNG
Holland
Pr Frans Cremers
Holland
Kliinilised uuringud
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression: (INTERCEPT-AMD)
Steroid Eye Drops Versus Placebo Eye Drops in Chronic Central Serous Chorioretinopathy Trial (PICS Trial)
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS).
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).
Safety and Efficacy of Emixustat in Stargardt Disease.
Natural History of the Progression of Choroideremia Study NSR-CHM-OS1.
Rate of Progression in USH2A Related Retinal Degeneration
A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.
Half-dose photodynamic therapy versus eplerenone treatment in chronic centralserous chorioretinopathy.
A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON).
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher
Natural history of the progression of X-linked retinitis pigmentosa.